<DOC>
	<DOCNO>NCT01067066</DOCNO>
	<brief_summary>The goal Phase I portion study find high tolerable dose TPI 287 give combination Temodar ( temozolomide ) patient metastatic melanoma . The goal Phase II portion study learn TPI 287 , give combination temozolomide , control metastatic melanoma . The safety combination also study .</brief_summary>
	<brief_title>A Phase I/II Study TPI 287 - Temozolomide Combination Melanoma</brief_title>
	<detailed_description>Study Drugs : TPI 287 design block tumor grow prevent cancer cell divide . Temozolomide design kill cancer cell cause break DNA ( genetic material ) cell . Study Groups : If find eligible take part study , assign study group base join study . Up 8 group 6 participant enrol Phase I portion study , 64 participant enrol Phase II . If enrolled Phase I portion , dose TPI 287 temozolomide receive depend join study . The first group participant receive low dose level TPI 287 temozolomide . Each new group receive high dose TPI 287 temozolomide group , intolerable side effect see . If participant dose limit toxicity , 6 additional participant add dose . If dose limit toxicity occurs , dose level consider maximum tolerate dose . If participant experience life threaten side effect , additional participant enrol dose level high dos give . An additional 3 participant treat dose level one life threaten toxicity . Once maximum tolerate dose combination find , Phase II study open . If enrol Phase II portion , receive drug combination high dose tolerate Phase I portion Central Venous Catheter ( CVC ) : You CVC place . A CVC sterile , flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form procedure . Study Drug Administration : You receive TPI 287 vein 1 hour ( +/- 10 minute ) Days 1 , 8 , 15 ( +/- 1 day ) 28 day study cycle . Before receive dose TPI 287 , receive dexamethasone , Benadryl ( diphenhydramine ) , Pepcid ( famotidine ) vein help prevent allergic reaction . You also receive drug prevent nausea vomit . Your vital sign measure 30 minute follow end infusion TPI 287 . Your vitals measure often , need . You take temozolomide tablet mouth Days 1-5 bedtime . You eat least 1 hour 1 hour take temozolomide . Study Visits : Before cycle , performance status record physical exam . You also ask symptom may experience drug take . On Days 1 , 8 , 14 cycle : -Blood ( 1 teaspoon ) drawn routine test receive TPI 287 . On Day 22 cycle : -Blood ( 1 teaspoon ) drawn routine test . Every 8 week , CT scan MRI scan check status disease . If brain metastasis , MRI brain every 4 week . If brain metastasis , MRI brain every 8 week . Length Study : You continue take study drug long benefit . You take study disease get bad intolerable side effect occur . End-of-Treatment Visit : About 4 week stop take TPI 287 combination Temozolomide , end-of-study visit . At visit , follow test procedure perform : - You physical exam . - You ask complication side effect may experience . - Blood ( 2 tablespoon ) draw routine test . - If doctor think need , CT scan MRI scan check status disease . This investigational study . TPI 287 FDA approve commercially available . At time , TPI 287 use research . Temozolomide FDA approve commercially available primary brain cancer . The use temozolomide combination TPI 287 investigational . Up 106 patient take part study . All patient enrol MD Anderson .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Patients histologically proven melanoma metastasis unresectable Stage III Stage IV . This include bulky stage III M13 . Patients melanoma documented metastasis brain eligible . 2 . Patients must show unequivocal evidence tumor recurrence progression least one indicator lesion , measure one dimension &gt; /=20mm conventional technique ( CT , MRI , Xray ) &gt; /=10mm spiral CT scan . 3 . Patients may two prior cytotoxic chemotherapy regimens disease ( immunological target therapy e.g . vaccine , IL2 , BRAF inhibitor , consider prior cytotoxic chemotherapy ) . Patient treat Docetaxel , Paclitaxel taxanes . 4 . All patient must sign informed consent indicate aware investigational nature study keep policy hospital . 5 . Patients must Eastern Cooperative Oncology Group status &lt; /=2 . 6 . Patients must recover toxic effect prior therapy : 4 week prior cytotoxic therapy and/or least two week vincristine , 6 week nitrosoureas , 3 week procarbazine administration , 1 week noncytotoxic agent , e.g. , interferon , tamoxifen , thalidomide , cisretinoic acid , etc . ( radiosensitizer count ) . Any question relate definition noncytotoxic agent direct Study Chair . 7 . Patients must adequate bone marrow function ( ANC &gt; /= 1,500/mm3 platelet count &gt; /= 100,000/mm3 ) , adequate liver function ( SGPT serum glutamate oxaloacetate transaminase ( SGOT ) &lt; /= 2.5 time normal , bilirubin &lt; /= 2 mg/dl ) , adequate renal function ( BUN creatinine &lt; /=1.5 time institutional normal ) prior start therapy . 8 . TPI 287 may interfere coumadin dose patient take combination require monitoring PT , PTT international normalize ratio ( INR ) . 9 . Females childbearing potential ( nonchildbearing define great one year postmenopausal surgically sterilize ) must use acceptable contraceptive method ( abstinence , intrauterine device , oral contraceptive double barrier device ) , must negative serum urine pregnancy test within 7 day prior begin treatment trial . Sexually active men must also use acceptable contraceptive method duration time study . 10 . Patient 15 year age old 1 . Patients brain metastasis must take primidone , carbamazepine , phenobarbital phenytoin anticonvulsant ( EnzymeInducing AntiEpileptic Drugs ) . Patients change anticonvulsant others allow must drug list least 1 week . 2 . Patients neuropathy . 3 . Patients uncontrolled high blood pressure , unstable angina , symptomatic congestive heart failure , history myocardial infarction within previous six month , serious uncontrolled cardiac arrhythmia . 4 . Because concern potentially harmful interaction TPI 287and medication take patient HIV positive AIDS related disease , patient HIV positive eligible entry study . Only patient suspect HIV test positive , ineligible . 5 . Patients history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) ineligible Phase II part study unless complete remission therapy disease minimum 3 year . However , Phase I part study , patient second malignancy eligible malignancy recur appropriate therapy . 6 . Patients : ) active infection , b ) disease obscure toxicity dangerously alter drug metabolism , c ) serious intercurrent medical illness , ) prior document recurrence temozolomide 7 . Females pregnant breastfeeding . 8 . Patients young 15 year age 9 . Patients prior therapy paclitaxel taxanes .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>TPI 287</keyword>
	<keyword>microtubule inhibitor</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Temodar</keyword>
	<keyword>cytotoxic agent</keyword>
	<keyword>unresectable Stage III</keyword>
	<keyword>Stage IV</keyword>
	<keyword>Metastatic Melanoma</keyword>
</DOC>